Timmerman Report is an independently-owned subscription publication that provides timely, in-depth biotech news and analysis. It’s for anyone who seeks to understand new drug development, diagnostics, genomics, and other technologies that are changing medicine.
I’m looking for the true innovations, the emerging trends, the market forces, and the characters at work. Because I’ve been covering the industry for more than a decade—through two busts and one and a half booms—I bring context to stories that few can match. Readers should expect big picture perspective, and a steady drumbeat of news, features, and original commentary.
This type of in-depth reporting will help prepare you for your next big meeting, find a partner, jump on an investment opportunity, hire an up-and-comer, get to know the people you work with, or land a job.
My goal is to write accessibly for all of you: in a way that specialized readers can appreciate and lay readers can understand. It’s the sort of clear, probing and contextual journalism that never goes out of style.
I look forward to serving you, the biotech reader, for years to come.
I focus on the full spectrum of science, technology, medical evidence, regulatory issues and business strategy. I study how these things affect all kinds of organizations—everything from startups on their first $1 million to academic institutions to established companies. Subjects range from cancer to Alzheimer’s to genetic diseases and conditions that scientists are only beginning to adequately define.
A few examples of the kinds of reporting I do:
News you can find all over the Internet.
Send me a note at firstname.lastname@example.org. Or, send an anonymous tip.
Yes, Timmerman Report will occasionally run guest editorials. These posts should generally be about a timely, relevant theme to biotech industry professionals; be written in a clear, conversational style consistent with the site; have a clear opinion that isn’t complete conventional wisdom; and be 800 words or less. If I decide to accept your submission, I will give it significant editing attention to help you improve your writing. It’s one advantage of posting on Timmerman Report. Email submissions to email@example.com.
Yes. This license grants companies the right to share Timmerman Report content freely within their companies, based on average estimated usage. Call me at 206-419-7575 to place an order on one of four tiers:
Small: 50 employees or less / 5 readers: $500
Medium: 50-500 employees / 15 readers: $1,500
Large: 500+ employees / 35 readers: $3,500
X-Large: 5,000+ employees / 100 readers: $10,000
About 3 stories per week. The Timmerman Report is focused on spending enough time on each story to deliver quality reports.
You’ll get an e-mail as soon as the story is published, plus a weekly roundup e-mail. All story alerts will be posted right away on Twitter: @TimmermanReport
Tinypass is the paywall software provider, and it uses Braintree Payments as the payment processing vendor. Tinypass also gives you the option of paying via PayPal or Amazon.
When you purchase a subscription to Timmerman Report, you will be billed by Tinypass, and Tinypass will send you an e-mailed confirmation and a receipt. If you don’t see a receipt within a few minutes, check your spam folder. If you still don’t see a receipt, write to firstname.lastname@example.org.
No. As long as your web browser allows cookies, you will be automatically signed in every time you come to Timmerman Report. If you want to sign in on a second device, like a tablet or smartphone, then you will have to sign in once on that device, too.
The Timmerman Report Gives You Consistent In-Depth Reporting on Biotechnology. Get Your Edge.
Luke Timmerman sets the standard for excellence in biotech journalism. His brand of tough, intellectually honest, independent reporting is essential for our industry.
Timmerman is always ahead of the game.
Today’s biotech social media is easy to obtain, but is a firehose of data, information, and speculation. The savvy professional needs less noise and more actionable signal. Luke Timmerman finds and writes about that signal.
Luke’s ability to blend the implications of science with the exigencies of business creates an idiosyncratic and insightful read.
Meryl Schenker Photography
Luke Timmerman is an award-winning journalist who has been covering biotechnology since 2001. Luke has written about the industry for a regional mass media publication (The Seattle Times), a global financial audience (Bloomberg News), and a successful online startup (Xconomy). He is working on his first book, “Hood: Trailblazer of the Genomics Age.”
Luke was named one of the “100 Most Influential People in Biotechnology” by Scientific American Worldview in 2015. He has won a number of reporting prizes, including the Scripps Howard National Journalism Award, the Association of Health Care Journalists Award, and has twice been named a finalist for the Gerald Loeb Award, the highest honor in business journalism. Luke is a regular commentator on KUOW, Seattle’s public radio station, and is a frequent speaker and moderator at biotech industry events. A farm boy from southwestern Wisconsin, Luke went on to earn his bachelor’s in journalism from the University of Wisconsin-Madison in 1997. For the 2005-2006 academic year, he was selected as a Knight Science Journalism Fellow at MIT.
In his spare time, Luke enjoys running, mountaineering (hence, the mountain logo), fantasy baseball, and watching the Green Bay Packers and Wisconsin Badgers. He lives in Seattle with his wife and daughter. When he’s not banging at his keyboard or flying to biotech conferences, you can find him running on the Myrtle Edwards Park trail or lugging a heavy backpack up the Blaine Street Steps.